Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: J Orthop Res. 2014 Jul 1;32(10):1349–1355. doi: 10.1002/jor.22671

Table 3.

Percent of devices that processed blood from OA donors to form APS with improved (> 1.0) Anti-IL-1 Cytokine Blocking ratios ([IL-1ra + sIL-1RII / IL-1β]APS / [IL-1ra + sIL-1RII / IL-1β]Blood), Anti-TNFα Cytokine Blocking Ratio ([sTNF-RI + sTNF-RII / TNFα]APS / [sTNF-RI + sTNF-RII / TNFα]Blood), and Combined Anti-Inflammatory Cytokine Blocking Ratio (([IL-1ra + sIL-1RII / IL-1β]APS / [IL-1ra + sIL-1RII / IL-1β]Blood) or ([sTNF-RI + sTNF-RII / TNFα]APS / [sTNF-RI + sTNF-RII / TNFα]Blood)).

Ratio % of Devices with Improved Cytokine Blocking Ratios
Anti-IL-1 Cytokine Blocking Ratio 90.8%
Anti-TNFα Cytokine Blocking Ratio 89.8%
Combined Anti-Inflammatory Cytokine Blocking Ratio 98.0%